Back to Search
Start Over
Penicillin-Binding Protein 5/6 Acting as a Decoy Target in Pseudomonas aeruginosa Identified by Whole-Cell Receptor Binding and Quantitative Systems Pharmacology.
- Source :
-
Antimicrobial agents and chemotherapy [Antimicrob Agents Chemother] 2023 Jun 15; Vol. 67 (6), pp. e0160322. Date of Electronic Publication: 2023 May 18. - Publication Year :
- 2023
-
Abstract
- The β-lactam antibiotics have been successfully used for decades to combat susceptible Pseudomonas aeruginosa, which has a notoriously difficult to penetrate outer membrane (OM). However, there is a dearth of data on target site penetration and covalent binding of penicillin-binding proteins (PBP) for β-lactams and β-lactamase inhibitors in intact bacteria. We aimed to determine the time course of PBP binding in intact and lysed cells and estimate the target site penetration and PBP access for 15 compounds in P. aeruginosa PAO1. All β-lactams (at 2 × MIC) considerably bound PBPs 1 to 4 in lysed bacteria. However, PBP binding in intact bacteria was substantially attenuated for slow but not for rapid penetrating β-lactams. Imipenem yielded 1.5 ± 0.11 log <subscript>10</subscript> killing at 1h compared to <0.5 log <subscript>10</subscript> killing for all other drugs. Relative to imipenem, the rate of net influx and PBP access was ~ 2-fold slower for doripenem and meropenem, 7.6-fold for avibactam, 14-fold for ceftazidime, 45-fold for cefepime, 50-fold for sulbactam, 72-fold for ertapenem, ~ 249-fold for piperacillin and aztreonam, 358-fold for tazobactam, ~547-fold for carbenicillin and ticarcillin, and 1,019-fold for cefoxitin. At 2 × MIC, the extent of PBP5/6 binding was highly correlated ( r <superscript>2</superscript> = 0.96) with the rate of net influx and PBP access, suggesting that PBP5/6 acted as a decoy target that should be avoided by slowly penetrating, future β-lactams. This first comprehensive assessment of the time course of PBP binding in intact and lysed P. aeruginosa explained why only imipenem killed rapidly. The developed novel covalent binding assay in intact bacteria accounts for all expressed resistance mechanisms.<br />Competing Interests: The authors declare no conflict of interest.
- Subjects :
- Penicillin-Binding Proteins genetics
Penicillin-Binding Proteins metabolism
Bacterial Proteins metabolism
Network Pharmacology
Microbial Sensitivity Tests
beta-Lactams pharmacology
beta-Lactams metabolism
Imipenem pharmacology
Imipenem metabolism
Ceftazidime metabolism
beta-Lactamases metabolism
Anti-Bacterial Agents pharmacology
Anti-Bacterial Agents metabolism
Pseudomonas aeruginosa metabolism
Subjects
Details
- Language :
- English
- ISSN :
- 1098-6596
- Volume :
- 67
- Issue :
- 6
- Database :
- MEDLINE
- Journal :
- Antimicrobial agents and chemotherapy
- Publication Type :
- Academic Journal
- Accession number :
- 37199612
- Full Text :
- https://doi.org/10.1128/aac.01603-22